IMGN - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome, everyone, to this ImmunoGen Second Quarter 2018 Financial Results Conference Call. Today's call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Sarah Kiely, Investor Relations and Corporate Communications. Please go ahead, ma'am.

Sarah Kiely

Good morning, and thank you for joining today's call. a progress that operating and issued of a results. we recent our second today, press includes release summary Earlier quarter XXXX be This the section the and our found can of immunogen.com. press Investors under at recording website the release call of

our are for and our Officer, Berkenblit; and CEO, CFO, will Chief the Scientific Dave Johnston. join today Chief call Mark Officer, team Medical Q&A the session. President On our the Anna our Enyedy; Rich Gregory,

and review will milestones we today's accomplishments results of key During quarter highlight and second recent for the call, financial year. remainder the

During With our in and investment the such I'll call the that, uncertainties differ Mark. discussion, statements. we results from filings. an with ImmunoGen will now use turn are forward-looking statements, materially to risks associated over actual included and Descriptions in the of SEC may our

Mark Enyedy

Thank everyone, you, for today. thank joining us you Sarah. morning, and Good

we the progress program, our lead significant second positive sheet. During by and balance quarter, momentum, led with our soravtansine continued mirvetuximab our strengthening

we've the completed which of a supporting financial primary months registration strength we through in our ADCs As XXXX. in with ovarian innovation for and accelerating the on and and of leadership us third, ahead women nicely enrollment of set objectives these building milestones completing last IGN half the for treatment in positions for that number We novel the expanding launching by of innovation; months. trial in achieved mirvetuximab important on high-value X Phase a XXXX; development reach of April, endpoint patient first, the ImmunoGen, X position our cancer partnerships. FORWARD of mirvetuximab, second, the several reminder, through programs; at first continued for In business priorities pipeline schedule, readout a finally, III our strategic the maintaining I,

the data our earlier by we recently tolerability strategy. for in in additional II step which activity forward FORWARD multiple FORWARD positive ESMO cohort with FDA which the of body cohorts May ASCO, conjunction an and of and for reported fast-track encouraged combinations treatment carboplatin and Avastin In data mirvetuximab, favorable our designation We from in in across study, is registration this evaluating demonstrating also received II, initial June, October. of expansion sharing is cohorts from cancer. look ovarian we We're and at Keytruda to lines growing mirvetuximab the data important

the our cash our during position an we Finally, approximately stock, of offering common sheet. million to net $XXX quarter, strengthened oversubscribed and upsized our with proceeds in second public adding balance

runway readout well anticipated I of trial. line FORWARD Importantly, this the beyond extend top our the capital

report turn X So mirvetuximab more detail the call the program. business we're With pleased to the for made continued the that, XXXX. of with I'll to Anna review first to Anna? momentum we've over with the in progress months the

Anna Berkenblit

you. Thank

FORWARD we the of track mentioned, top are on As from our Mark half of continued first line registration pleased to report trial progress ovarian I the in platinum-resistant in with the and trial XXXX. data cancer

high folate is the in and FORWARD study the in high the population activity as in receptor and a clinical both we includes alpha the setting. on safety as in and PFS, studies subset folate alpha chemotherapy observed mirvetuximab to As believe single-agent that treatment expressers progression-free encouraging receptor a with Based entire as the profile consistent has the date, to expression. platinum-resistant of potential I survival, endpoint well reminder, displace primary patients in medium or

FORWARD II from is into patient recently for of combination reported cancer to with regimens as II for study. underway part we're of a in Avastin study is single-agent focus the mirvetuximab cancer. addition with patients in carboplatin and our of patients in and our the combination expand which platinum-resistant the with in mirvetuximab This cohort ovarian treatment folate of alpha the also recurrent Today, IbX move mirvetuximab Avastin that plus combination carboplatin, FORWARD lines with foundation now combination cancer FORWARD our Keytruda earlier I'll FORWARD II. II population strategy, enrolled or triplet ovarian to receptor our data and In evaluating ovarian laid trial. Phase positive eligible platinum-sensitive on

safety combination that in can June, from receptor We alpha and XX full we tolerability. positive have encouraging The of events patients over known patients X cancer. activity ovarian established PARP X were population adverse Avastin up data mirvetuximab profiles with full having therapy be with dose ASCO agent. Avastin, the with XX% cohort, combined safely evaluating The and a of and observed with each presented this of XX% received to favorable Keytruda demonstrating prior of prior carboplatin tolerated, received with of inhibitor. prior consistent overall mirvetuximab in and combination Avastin, the with folate platinum-resistant doses of lines well was expansion median At

or XX the with confirmed X.X PFS months. of ORR, the was evaluable response, a XX% rate, For patients median overall response for

Importantly, in alpha X.X XX of patients median receptor confirmed X lines PFS a response and months therapy, medium median and to or of folate XX.X matched high ORR the I with prior the XX% was of FORWARD months. duration X a subset of of expressions with

that in as of the study. monotherapy We is this our particularly excited the same I for are patients, about subset potential of FORWARD combination the which

analyses of year, As X.X a single of agent. a in ASCO X.X the as a pooled of PFS mirvetuximab reminder response with showed population months median median this last and months from duration

ovarian the with mirvetuximab and or progression-free provide XX% benefits, with PFS also receptor to the improved platinum-sensitive of been accepted from an XX Oncology. high rate Initial carboplatin, which response median ASCO from plus appears publication is confirmed medium with duration findings confirmed a median XXXX to a of a alpha XX impressive With combination Of follow-ups, the expressions, XX.X ORR XX% of in pleased response PFS at XX% response. the in PFS manifested confirmed with of rate subset data XX presented had of recurrent folate cohort was for evaluable longer provide mature Gynecologic patients now note, were months. a in with We evaluating survival showed longer cancer median by months. So months. dose-escalation XX the patients

combination continues favorable tolerability. this to Importantly, display

Taken evaluating together, mentioned cohort the I from the plus expansion combination Avastin and platinum-sensitive triplet mirvetuximab earlier, Avastin and cohort in carboplatin with that the support both disease. findings encouraging recurrent ongoing carboplatin patients

assessment Keytruda combination looking Another at mirvetuximab is ongoing. plus

In have additional mirvetuximab expression mirvetuximab's the we at program. have so expansion patients, of XX presented You'll clinical March findings use from medium in receiving with recall XX on cohort will patients progress alpha with expanded folate in additional October. we've of we at data with clinical data significant evidence Avastin made ESMO than data this encouraging by ovarian or in whom year-end. that cancer. patients from encouraging FORWARD And on received culminate year mirvetuximab XX Keytruda initial our SGO. will The report XXX receptor more we have growing combination closing, II generated high far who and combination We supports this believe body from this this

I'll over turn financials. call Dave the Now to to our review

David Johnston

Anna. Thanks,

morning's Our review financial press results this were the detailed highlights. release, so just I'll in

second our With approximately second in net the were our for the development balance $XX FORWARD million added successful of continued which a costs our IGN cash facility driven to also included expenses quarter position call, due quarter of our were financial the core of and largely at $XXX,XXX and maintain advancement is expenses of of were mentioned million the to to related noncash, our broad influx, included the of have in as well equivalents. our million, million guidance and ADCs in second programs, We're the the the our Revenues expenses. Mark strength described updating partnerships. as in in support with and the this Operating high-value leadership one approximately quarter I. reduction to this of G&A our In quarter to As beginning mirvetuximab, proceeds the million, research restructuring the $XXX sheet. a development for ended completed we release. XXXX. objectives expenses, largely we press Norwood earlier-stage June, the cash $XX charge $XXX remainder $X.X offering, to of clinical trial related decommissioning workforce second Operating by approximately

million no from guidance. be $XX change prior to revenues $XX is and expect We million, which between

$XXX expect we expect And to between change guidance. and in and million well of million million, at to fundraising be guidance $XX about costs. our $XXX accelerated cash $XXX operating is We which between million, million trial as the higher, be recent reflecting our primarily $XXX our $XXX compared expense clinical $XXX previous expenses million year-end to due as operating and to million the between

to operate mirvetuximab advancing our focusing continue with on financial towards market. the discipline, resources We

III Phase extends that year first is XXXX. in of half a a strong the expected FORWARD readout with runway Our beyond financial I position of at the the least trial cash

now me the So let to with Mark. call over hand back that,

Mark Enyedy

Thanks, Dave.

the productive first The look milestones the remainder half for of forward to year. company, the important highly a number XXXX for of and of has been we

we highlighted, will expansion from in mirvetuximab and the at report data October. cohort Anna Keytruda ESMO As

also in I with ongoing. Phase IMGNXXX pipeline progressing is hematologic our malignancies of Our IGN IMGNXXX studies and

We that, we these novel evolution initiate for short, also in expect end MacroGenics with the before are December, on about activities we at the with IND-enabling from expect execution and and to to pipeline. and ASH a of call programs With to are XXXX focus questions. ADAMX the we'll in open our share we for the the program continue move data of the with collaboration Meeting through progress encouraged our year. making In ImmunoGen Annual

Operator

from Jefferies. [Operator question take Instructions]. your We'll Biren from first Amin

Biren Amin

ask the alpha just start just Maybe I could the if how FORWARD study split. on I and with

will PFS, as at and high I both it Or well think the alpha Will split both across hierarchical? medium be alone. a high Is subsets how that subsets? the is first? Anna alone be you evaluating as mentioned you're And high evaluated? looking

Anna Berkenblit

Thanks, Biren.

is So the as high high as at and we're subset. the well in survival the population, medium which looking intent-to-treat group, progression-free

Hochberg what's using the We procedure. are called

simultaneously the the in If other. So claim less than hand, is in the ITT and but needs in hierarchical testing, on not this one, the less rather than test we to PFS both the is value in in subset. and If it we high other high the than P greater the X.XX be ITT the is X.XX success X.XXX both. subset,

Biren Amin

FORWARD just it. then I. Got And on

about that X the Can the talk arm? control is agents. enrolled, Now the the arm of trial in split that those for allows you you've across fully X chemotherapy investigators enrolled choice different control

Anna Berkenblit

the choice I on are What Doxil this So There's X lines include and to we patients nice allowed topotecan, of X is at we have X options. anticipated. enrolled options all paclitaxel, that prior choice investigator patients can distribution as have a would you tell therapy. investigator and point

Biren Amin

question. And it. Got then one maybe last

data. combo with are regimen? you've plans ESMO, mirv-Keytruda at some we're into data the sure what this next I'm anticipating the got As insights for

how about this combination? plan bit little a talk you to you can So develop

Anna Berkenblit

Sure.

So we we Enrollment based enrolled saw in cohort the the the on cohort completed escalation. in rather promising recently. data expansion expansion

And based and That efficacy but reasonable to saw would rate, for will cohort high we pathways to us data So status and, in that see quite Merck the continue early at regarding with this, have expansion initial similar patients the XX potentially, medium receptor encouraging. a would a data with with initial continue With on data ESMO it's should toward perspective be engage the we expressions. FDA that up approval anticipate to being response follow-up, hold PFS we an escalation, the cohort prompt a objective from data certainly overall, meaningful to our from XX bit if read us single-arm if perspective. will duration-of-response said, study. of whom that to or accelerated alpha the have reasonably breakthrough a data looks to conversations on expansion longer be a what folate for the

Operator

hear Newman from We'll next from Cannacord. John

John Newman

question Just the combination. on the of plus mirvetuximab had a Avastin development

well Avastin about help order as term, comment combination you're curious, in if get how term. looking or off-label you're mirv it recent enough curious on how you FORWARD that generating You've the And where potentially I'm plus -- also of the recently should about long plus use hands that data Avastin data just you're you if combining II. the patients? at generating doctors I started as the mirv I'm wonder walk at thinking the can in that MANGO and ASCO about something thinking just could you're in arm physicians MITO/MANGO continued in that triplet, utilize just plus and to through so could carboplatin data long else. thinking if us

Anna Berkenblit

Thanks, John.

John. a compendia other for the concept mirv, a So plus registrational intent, full on as full out proof regimen, also look next be, depending after be data be encouraging data we data safety focus maintenance dose plus is doublets, couple thus triplet efficacy safety would the we we and which proceed the component and pursue larger mirvetuximab would If activity go have a to Avastin study and robustness the efficacy will far, completion initially with the get the Avastin. disease. data. initial to and/or III dose of listing would both they of to cohort One would the clearly of study. point of now be just sufficient dose this doublet But but of mirvetuximab enrolling be based Phase on explored to Based and program really our data a carboplatin. are And therapy. One to options, are recurrent much we two the the study. promising generate We're level with is rapidly Avastin these as carboplatin, signal. we for carboplatin those antitumor triplet combinations, from out, single-arm mirvetuximab you on And generated now, randomized right platinum-sensitive of continue at not in consider what really the to the the have criteria to identify as would hope we as full and on evidence back enrolling going we've

you, survival don't order should mind cohort pretty Now know. of -- the the doublet. for carboplatin with It's months with this long XX be the just on progression-free I

surprised that. be if than So would I longer be wouldn't it

sometime your question. And MITO/MANGO probably next will year. first So be available data

the the disease, So June, MITO/MANGO This important and of that, just therefore, I setting Avastin regimen. Avastin with data effective because study Avastin cancer. if after disease, just Avastin-based non-Avastin-containing was disease as setting. at of And combination Therefore, now for in in platinum-sensitive is the retreatment U.S. setting therapy gotten Avastin who patients as repeated our Avastin that at presented platinum-sensitive effective. demonstrating use Phase recurrent data implications III platinum-resistant the line in an after surprised has ASCO also in Avastin recurrent wouldn't front be ovarian plus platinum-resistant initial ASCO we that is MITO/MANGO mirvetuximab approved also is recurrent find in a the wide use use in as the supports platinum-sensitive we had not presented but after Avastin is in

Operator

Cowen. from Peaker Boris

Boris Peaker

discussion you studies. several -- mean, are continue that mentioned me that initially Let combo considering. maybe just options there start you're on the I

randomized You're you a it's if deciding route? kind timeline have waiting answer the you sand that some data study. you you Phase on curious, a now or to commence the mature kind before III right just whether think is there compendia listing Phase -- if go decide potentially such of strategy or where to where -- draw the of in randomized to you III think I'm study

Mark Enyedy

cover So the this will Boris, certainly at Keytruda. we'll the ESMO initial with cohort expansion in data have responses

have an the view, safety the durability for of next responses we'll those perspective we'll half say, the in quarter, combination. expectation we and, FDA triplet initial first think respect again, on the -- a first to I our approach -- may the that in support those initial that I an the that in to of Separately, would so responses year we're with And seeing patients. that combination, in is the have certainly

those we'll first of you in those on have events both to tell the And of did think of perspective cohorts. that? so add both next half to Anna, year, I anything that want reasonable us a

Anna Berkenblit

that's exactly right. think you. I No, Thank

Boris Peaker

what you question second Could my maybe good coming maybe data ESMO expectations would And data the with you. be? of is set Got some up.

Anna Berkenblit

Sure.

lines ovarian of in X PARP and of with months. initial approval their subset got with about a a XX% to the of response accelerated X around therapy, prior based X in on patients mutations of So BRCA of response cancer recurrent rate duration

So subset. type that really wild applies to that therapies BRCA approved BRCA setting. mutant in the no patients have

of patients, efficacy that. that, around we sort that of in for a provides and FDA think engage would of the and be our rate we meaningful that perspective, would response conversations combination response if level So duration from benefit

Operator

Jessica from next Fye from hear We'll JPMorgan.

Jessica Fye

on for up following think question I expectations setting and prior just ESMO. the one, Boris

better duration-of-response I of patient a enrolled last range you've in there's many like lows comment immature. whether of on when XXX talk patients? Can receptor the think alpha mentioned could how or folate value, me data worse we'll on could at and we levels little the tend about data to what be And then the do do new absence little bit moved point? was dose this can lastly, see at And you highs remind expect prognostic ESMO ADC yours? through than having you for follow-up i.e., you can also you on a

Anna Berkenblit

Okay.

last on Keytruda the So ASCO. the was in patient arm after

do that entire it's of rate a that patient duration I of set. have response to cohort. of start overall responds. the beginning only we remember response response, will duration you the data immature a relatively So be once going the may counting you believe for But

take patient have So the to ticking. it might months a response then and few clock starts for a

report us I over why response we require again, have that that's improve confirmed want But So scans. only time longer that may caution because we two may initial even responses, follow-up, to with which rate. overall

have studies on question, the suggesting are do high a best some Phase to the map. know there's prognostic of poor survival There with published, papers is also with small alpha folate study. that, with options. we results factor, receptor no may the Therefore, there's pretty retrospective papers III lot folate actually other folate been factor standard-of-care a impact second overall prognostic alpha. published, receptor worse suggesting that all randomized and folate that receptor on mirvetuximab There of a with much and your papers alpha that For they're our are receptor we But chemotherapy. expression know as over we don't standard-of-care patients who appear won't until do alpha

see our data which question. Phase III from trial excited So the again, we're answer that to will

to in and we gears our and started switching Phase January this on conjugate, dose-escalation I enrolling hem study our IMGNXXX is antibody-drug Moving to year. CDXXX-targeted programs. the of

are plus We will in have data all as X the we moving possible share ASH. that and as we X design, at the quickly

Operator

next Capital from MacKay Markets. RBC hear Kennen We'll from

Kennen MacKay

the questions upcoming kind expectations there the get overall to XX a to average those of that of follow-ups. X? X to what high. of of see sort combo sort trying the PFS And we PD-X understand couple wanted And that will the get a for on follow those more Anna the get sort of had medium, set. we and duration of quick duration-of-response to here. for are evaluable and understanding I in of in better up again expecting ESMO be questions data are I and sort on I'm I XX patients we X that then where evaluable? curves will Should like curves very or sort could had

Anna Berkenblit

Okay.

Jess's addressed the may is measuring and a until start response, patient I you I can to isn't would words, only response, response. In be during of of in don't few duration like it patient patient the pointed duration until you other take months have so when progresses. a it censored the question, a then you out, that So analysis, response Kennen, And once -- have endpoint. the measured

the efficacy. first here. year. half hopefully peak of not mature the example, look introduce at we're it to to duration-of-response as We next safety will updated because as for want combination that initial ESMO, on forward don't data data the the presenting This the cohort, I our meaningful having data, We of well to into an bias. cohort initial and from going be confirming manage expectations So could anticipate really report

Kennen MacKay

thought doing very was there And listing surrounding like compendia questions follow-ups. with then had for looks a the initial Okay, a then is about randomized just either obviously quick just than And if opposed very data precedent I'm forward this [indiscernible], quick maybe two on prior if One Phase triplet combo III through at the wondering any combo better SGO but Avastin to follow-up actually pembro. early, data was The clear. you a data. as path route. that. combination combo pembro

approval a with experimental a either specific accelerated through two an indication, listing? or getting aren't instance For approved therapies approval compendia in getting or that together yet

Anna Berkenblit

Okay.

triplet pemetrexed to love pembrolizumab the let So first approved in unsolicited mirv, carboplatin the We would start line because carbo, lung and triplet, me cancer setting. do for now is with with pembro. in patients that particularly

mirvetuximab high I the imagine a So say combinations. And Keytruda plus hope plus as with be evolve mirvetuximab doublet with data very of trial. that conversations drug-only to can advance we in triplet. is exciting ongoing Avastin receptor a could the continued and carboplatin variety Merck I also tumors we collaboration pembrolizumab triplet how about the from a settings evolve, our could have have folate Keytruda data and I for All for plus

Regarding about novel-novel your question the for based of single-arm on therapies potential second approval an data.

precedents Our add strategy really There on out is the approved mirvetuximab really there. headed. to with platinum-resistant it so to and are where setting are in then Keytruda, get we're that's that and

For example, But the a agents being those pathways with without data inhibitor combination of were approved. approval. on for those single-agent prior body building individual RAS/RAF/MEK combining

best development. of thinking necessarily is about it's drug accelerating are flexible So more in the That terms how being said, they becoming precedent. FDA not

it can approval. what of I the with up, we patients' hold our level be need, all if data conversation of would to say So having data will evidence worth regulators how is an many a about accelerated worth support

Kennen MacKay

very Got then clear. just And was that -- you.

on quick follow-up a Just that point.

FDA. market potentially the biomarker, which it's lower the of for slightly here, think may different for so be of had requiring like the Is pembro-mirv smaller maybe a on and case had, sort in an could which again, PARPs patients it or not for a PARP population, the bar lower makes just sort approval rate there, and the that requirement you bar, accelerated the on inhibitors response referenced You'd eye And of of that you something maybe was because a with the over for a approval the bar mentioned. combo? have that you gaining and duration sort that XXX --

Anna Berkenblit

be so to we have ovarian still, we're Well, that XX% opposed folate focused alpha to encompasses the receptor of would XX% with on the patients, to But biomarker. clear, cancer medium mutations. high BRCA population as a the

there also wealth plus mirv with we data now patients, again, mirvetuximab a and a more data pretreated have wealth heavily So is pretreated Keytruda, of in Keytruda for for monotherapy of in heavily patients.

So receptor could think wild benefit to or with the BRCA positive again, of folate I alpha, combination patients, lines therapy. X type prior high medium X

Operator

Chatoopadhyay H.C. hear from Wainwright. We'll next Debjit from

Earl DeSouza

I'm in for Debjit, Earl DeSouza.

So two questions on our side.

do post-ESMO, sheet, First, your two, its Amgen for given logical ADCs with environment balance Question for kind last to the early registrational And a FORWARD slew read out this XXXX? stop for differentiating of ADC program BCMA setbacks how I you culminating of or, the how night, ImmunoGen decision does study going to ADCs? wait is is And given most which to results? proceed mirvetuximab? first the for in the change

Richard Gregory

ADCs. rather Actually, Rich a at environment environment around maybe the one moment. it's the it's think I'm I first Gregory. about positive taking the So

we the and There's at the at last additional HERX approvals such cancer Immunomedics' multiple as drug new looking had you're If drug, X look Daiichi you breast mirvetuximab. space. year, programs, this in

I quite right now, development successful what ADCs examples about there's XX to in the programs at the be of moment. think there's in late-stage appear of and plenty clinic

of and trying level rigor all of very do we And payload, we and to be We wealth the differentiating we think is, field moment same drugs in experience. we is of differentiate the forward a it that pharmacodynamics programs a an ourselves is could a is And this at to what a as kind where bringing additional of sense where thought way ADC know -- great went PK good what thoughtful but apply and will accelerating look that's mirvetuximab to upon we ADC, each usual, for need to fail, have that an a target. think better. I have actually additional I we're curve. the we're new payers of example so like, into as a first, So lending on based

Seattle the people think think, I experienced of I same in there. to But us, experience at we're company have, right succeed field. ADC look the So claim set this Perhaps the we if you out thing. most can and

Anna Berkenblit

And it FORWARD the I'll do would take your after I or reads study next out. before second and we question, registrational regarding

recall from that FORWARD will half first have line may You I of we year. top data next

intent data hold Keytruda and accelerated for approval and the study combination if So then combination up, a engage on is, with FDA approval label conversation pursue our next registrational to our expansion. the an as next that

Operator

[Operator Andy Hsieh hear from next Instructions]. We'll Blair. from William

Andy Hsieh

I has switching a manufacturing believe, I have one, some mentioned it sites party. just to do commentary the you Mark, third about with to and manufacturing.

perhaps have third-party scale-up So if correctly, with different terms I you by studies it parties. supply transition for what update made of do to trial understand the mind the us in be clinical the your to do efforts and make will us supply partner? commercial you and Would reminding FDA comfortable the smooth

Mark Enyedy

Yes, sure.

the So question. for thanks

change for been manufacturers So no mirvetuximab. first, the there's in

X is manufactured manufactured payload mind Boehringer drug to this there case, So an linker antibody Ingelheim. keep components in conjugate. by the and Antibody, manufactured those the that shipped is Sigma-Aldrich, in then company in is is product. produce conjugator the then by substance a components are BSP, X by that's really The called for of Teva-Sicor. leading drug the to ADCs, and each drug to And world

of have for place manufacturers years at ImmunoGen. been And all so in those

the was in study. patients production. the no So And there of III Phase used product change the scale the in commercial majority in is

we're many are confusion quarter. early about first Norwood to early speak. mirvetuximab. batches to stage mirvetuximab. we and manufactured don't last production not material And of decommissioning clinical know, transitioning don't any produce respect as the decommissioning the clinical We earlier-stage those But being are of the elsewhere, decommission facility again, much are that facility the be there our for for some to by with substance, I we're years produced conjugation supplies the very maybe And -- Norwood components, issues our regulatory on used track drug BLA BSP. and various some comparability anticipate out of the we to programs, and of again, that to So plant will of transferred there.

Operator

time, callers host there this over to the turn queue. at I'd no like your the or are closing additional any back additional for comments. in to And conference

Mark Enyedy

thanks at interest you your our seeing very today. progress forward much to Great. Well, you update ESMO. again. for on to We all look and Thanks continuing

Operator

That thank you today's all participation. teleconference. for We conclude your does

You may disconnect. now

Immunogen (IMGN) 27 Jul 182018 Q2 Earnings call transcript